Cargando…
Tiotropium safety in ‘real‐world’ populations: Response to Schmiedl, et al. in the British Journal of Clinical Pharmacology
Autores principales: | Wise, Robert, Anzueto, Antonio, Dahl, Ronald, Dusser, Daniel, Calverley, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972173/ https://www.ncbi.nlm.nih.gov/pubmed/27197835 http://dx.doi.org/10.1111/bcp.12972 |
Ejemplares similares
-
The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes
por: Anzueto, Antonio, et al.
Publicado: (2015) -
Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial
por: Dahl, Ronald, et al.
Publicado: (2015) -
Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial
por: Wise, Robert, et al.
Publicado: (2015) -
The Tiotropium Safety and Performance in Respimat® Trial (TIOSPIR®), a large scale, randomized, controlled, parallel-group trial-design and rationale
por: Wise, Robert A, et al.
Publicado: (2013) -
Differences in outcomes between GOLD groups in patients with COPD in the TIOSPIR(®) trial
por: Dusser, Daniel, et al.
Publicado: (2016)